CTF18 Antibody

What is CTF18 and why is it significant in genomic research?

CTF18, also known as chromosome transmission fidelity factor 18 homolog, is a crucial 975 amino acid protein encoded by the human gene CHTF18. It plays a significant role in maintaining genomic stability by participating in the DNA replication block checkpoint, functioning redundantly with Rad24 . CTF18 is part of a larger replication factor C (RFC) complex, which is a seven-subunit structure that includes four small RFC subunits along with CTF18, DCC1, and CTF8 . This complex is essential for loading the replication clamp, proliferating cell nuclear antigen (PCNA), onto DNA, thereby facilitating DNA replication and repair processes . The CTF18-RFC complex specifically aids in the activation of the intra-S-phase checkpoint at stalled replication forks and assists in establishing sister chromatid cohesion . Research focusing on CTF18 is critical for understanding mechanisms of genomic stability, DNA replication fidelity, and chromosome transmission during cell division.

What detection methods are available with CTF18 antibodies?

CTF18 antibodies offer versatile detection capabilities across multiple experimental platforms. CTF18 Antibody (F-1), for example, is a mouse monoclonal IgG2a kappa light chain antibody that effectively detects CTF18 protein from mouse, rat, and human origins through various methodologies . These methodologies include:

• Western blotting (WB): For quantitative and qualitative protein detection

• Immunoprecipitation (IP): For protein-protein interaction studies

• Immunofluorescence (IF): For cellular and subcellular localization analysis

• Enzyme-linked immunosorbent assay (ELISA): For quantitative measurement

Researchers should optimize protein extraction protocols based on their experimental model, as CTF18 detection efficiency may vary depending on subcellular localization and protein-protein interactions within the RFC complex. When designing experiments, it's advisable to include appropriate controls that validate antibody specificity, particularly when investigating CTF18's interactions with other RFC complex components.

How should researchers validate CTF18 antibody specificity?

Thorough validation of CTF18 antibody specificity is critical for generating reliable and reproducible experimental results. A comprehensive validation approach should include:

• Western blot analysis: Confirm the antibody detects a band of approximately 975 amino acids (for full-length CTF18) in your species of interest. Compare results from wildtype and CTF18-knockout or knockdown samples when possible .

• Immunoprecipitation cross-validation: Perform reciprocal co-immunoprecipitation experiments with known interaction partners like DCC1 and CTF8 to verify that the antibody recognizes biologically relevant CTF18 complexes .

• Immunofluorescence validation: Confirm proper subcellular localization patterns, particularly nuclear localization consistent with CTF18's role in DNA replication . Compare staining patterns with published literature.

• Peptide competition assays: Pre-incubate the CTF18 antibody with the immunizing peptide (such as amino acids 25-75 for ABIN7453651) to confirm signal elimination in subsequent experiments .

For advanced studies investigating specific CTF18 mutations or variants, researchers should validate the antibody's ability to recognize these variants, particularly when studying patient-derived samples with potential structural alterations as identified in recent publications .

How can CTF18 antibodies be utilized to study DNA replication checkpoint mechanisms?

CTF18 antibodies provide powerful tools for investigating replication checkpoint mechanisms through several sophisticated approaches:

• Chromatin immunoprecipitation (ChIP): Researchers can employ CTF18 antibodies to detect association with specific genomic regions during replication stress. The C-terminus of Dcc1, a CTF18 binding partner, contains three-winged helix domains that bind to both ssDNA and dsDNA, facilitating chromatin recruitment of the CTF18-RFC complex . ChIP protocols should include appropriate crosslinking conditions optimized for replication fork proteins.

• Proximity ligation assays (PLA): This technique can visualize interactions between CTF18 and other checkpoint components like Rad24 or PCNA at stalled replication forks. The redundant functioning of CTF18 with Rad24 suggests important checkpoint control mechanisms that can be elucidated through these interaction studies .

• Immunofluorescence co-localization after replication stress: Treating cells with replication stress inducers (hydroxyurea, aphidicolin, or UV radiation) followed by co-staining with CTF18 antibodies and markers of replication stress (γH2AX, RPA, etc.) can reveal spatial and temporal dynamics of checkpoint activation .

• PCNA loading/unloading assays: Since the CTF18-RFC complex is essential for loading PCNA onto DNA, researchers can develop in vitro systems to assess how mutations or inhibitions affect this function, particularly during replication stress conditions .

When designing these experiments, researchers should consider cell cycle synchronization protocols to enrich for S-phase populations where CTF18 functions are most critical.

What structural insights inform experimental design with CTF18 antibodies?

Recent structural studies of the CTF18-RFC complex provide critical insights that should guide experimental design when using CTF18 antibodies:

• Domain-specific targeting: The CTF18 structure includes several functional domains including a nuclear localization signal (NLS), proline-rich domain, ankyrin repeat domain, and a triple barrel domain (TBD) where CTF18 interacts with DSCC1 and CTF8 . Antibodies targeting different domains may yield varying results based on epitope accessibility in different complexes.

• Structural changes in disease variants: Computational modeling using AlphaFold has revealed that the R751W variant makes more extensive contacts with RFC3-R9, changing the RFC-R9 rotamer conformation . This structural alteration may affect antibody binding, particularly for conformational epitopes.

• Clamp loader interface considerations: The clamp loader interface between CTF18 and RFC3 is structurally similar to the RFC1-RFC3 interaction, with key residues making specific contacts . When studying this interface, researchers should be aware that antibodies binding near this region might disrupt functional interactions.

• C-terminal interaction with Dcc1-Ctf8: The crystal structure shows that the last 76 residues of Ctf18 (residues 666–741) interact with full-length Dcc1 and Ctf8 . Antibodies targeting this region might interfere with complex formation or function.

When designing co-immunoprecipitation experiments to study the CTF18-RFC complex, researchers should consider these structural insights to interpret results accurately, particularly when investigating how mutations affect complex assembly and function.

What methodologies can elucidate CTF18's role in sister chromatid cohesion?

Investigating CTF18's function in sister chromatid cohesion requires specialized methodologies:

• Chromosome spread analysis: Using CTF18 antibodies in combination with fluorescent in situ hybridization (FISH) or chromosome-specific probes can help visualize cohesion defects in CTF18-deficient or mutant cells. Quantification of premature sister chromatid separation provides a direct measure of cohesion defects .

• Cohesion protein interaction studies: Co-immunoprecipitation with CTF18 antibodies followed by detection of cohesin complex components (SMC1, SMC3, RAD21, etc.) can reveal interaction dependencies. These experiments should be performed at different cell cycle stages to capture dynamic interactions .

• PCNA dynamics at sister chromatids: Since CTF18-RFC loads PCNA onto DNA, fluorescence recovery after photobleaching (FRAP) experiments using fluorescently-tagged PCNA in cells with wildtype versus mutant CTF18 can reveal how CTF18 influences PCNA dynamics at cohesion sites .

• Proximity-based labeling techniques: BioID or APEX2 fusion proteins with CTF18 can identify proteins in close proximity during cohesion establishment, potentially revealing novel interaction partners beyond the known RFC complex components .

These experimental approaches should be coordinated with cell cycle synchronization to focus on the specific phases where CTF18 contributes to cohesion establishment, typically during S-phase.

How can CTF18 antibodies contribute to immunological research?

Recent findings connecting CTF18 function to immunological development open new research avenues:

• T-cell development analysis: Researchers can employ CTF18 antibodies to investigate protein expression and localization during T-cell development stages. Flow cytometric analysis of thymic and splenic populations can assess developmental abnormalities related to CTF18 dysfunction . The following table summarizes key T-cell populations that should be examined:

• Hematopoietic development studies: CTF18 antibodies can be used in combination with hematopoietic stem cell markers to investigate lineage commitment and differentiation. Markers such as cKit and Sca1 should be included to assess early progenitor populations .

• Gene expression regulation: Chromatin immunoprecipitation sequencing (ChIP-seq) using CTF18 antibodies can identify genomic regions where CTF18 may influence gene expression in immune cells, particularly looking at genes involved in T-cell receptor rearrangement and expression .

• Replication stress in immune cell development: Developing lymphocytes undergo rapid proliferation and gene rearrangements that may induce replication stress. CTF18 antibodies can help investigate how its checkpoint functions specifically operate in this context .

When designing these experiments, researchers should consider using compound heterozygous Chtf18 R745W/E845Q models that mimic patient mutations to understand pathological mechanisms .

What strategies can effectively investigate CTF18 mutations in patient samples?

CTF18 mutations have been identified in patients with immunological disorders, requiring specialized investigative approaches:

• Mutation-specific antibody validation: When investigating patient samples with known CTF18 mutations (such as R751W or E851Q), researchers should first validate that their antibodies can recognize the mutant proteins. Western blot comparison between wildtype and mutant samples is essential .

• Functional assays with patient-derived cells: CTF18 antibodies can be used in immunoprecipitation experiments with patient cells to assess complex formation with RFC subunits, DCC1, and CTF8. Reduced interaction may suggest pathogenic mechanisms .

• Structural analysis of mutant proteins: Complementing antibody-based studies with computational modeling approaches like those described for the R751W and E851Q variants can provide mechanistic insights. The following computational techniques should be considered:

  • AlphaFold-Multimer modeling of CTF18 variants

  • Coordinate constrained protein relaxation using Rosetta

  • Structural analysis of contacts between CTF18 variants and RFC3

• CRISPR-engineered models: Patient mutations can be recreated in cellular or animal models using CRISPR genome editing, creating valuable research tools for antibody-based studies. The knockin mutations should include silent mutations that inactivate the PAM site to prevent re-cutting of the repaired allele .

For proper experimental controls, researchers should generate compound heterozygous models (e.g., Chtf18 R745W/E845Q) that accurately reflect patient genotypes rather than simple knockout models that may not capture the specific mechanisms of pathogenesis .

What optimization strategies improve CTF18 antibody performance in challenging applications?

Optimizing CTF18 antibody protocols can significantly enhance experimental outcomes:

• Epitope accessibility considerations: CTF18's involvement in the seven-subunit RFC complex may limit antibody access to certain epitopes. For applications like immunofluorescence or immunohistochemistry, optimized fixation and permeabilization protocols are critical:

  • Cross-linking fixatives (paraformaldehyde): Preserve structure but may mask epitopes

  • Denaturation (methanol/acetone): Improve accessibility but disrupt some conformational epitopes

  • Epitope retrieval methods: Heat-induced or enzymatic treatments may be necessary for formalin-fixed tissues

• Signal amplification approaches: For detecting low-abundance CTF18, consider:

  • Tyramide signal amplification for immunohistochemistry

  • Conjugated secondary antibody systems (HRP, fluorescent) matched to application sensitivity needs

  • Available CTF18 antibody conjugates include agarose, HRP, PE, FITC, and various Alexa Fluor® options

• Background reduction strategies:

  • Pre-absorption with non-specific proteins from the same species as samples

  • Optimized blocking solutions (BSA, normal serum, commercial blockers)

  • Careful primary antibody titration to determine optimal concentration

• Co-immunoprecipitation optimization:

  • Buffer composition adjustments based on complex stability

  • Cross-linking protocols for transient interactions

  • Antibody orientation strategies (direct coupling vs. protein A/G approach)

When troubleshooting, perform parallel experiments with multiple antibody clones or lots when possible, as epitope recognition can vary between antibody preparations.

How can researchers effectively analyze CTF18 in different subcellular compartments?

CTF18's functions in DNA replication and chromatin association require specific approaches for subcellular analysis:

• Nuclear extraction protocols: Standard cell lysis buffers may not efficiently extract nuclear-bound CTF18. Consider specialized nuclear extraction protocols:

  • Low salt buffer followed by nuclear lysis buffer with nuclease treatment

  • Gradual salt extraction to distinguish loosely versus tightly bound fractions

  • Chromatin fractionation to separate soluble nuclear from chromatin-bound CTF18

• Immunofluorescence co-localization approaches:

  • Counter-staining with markers for specific nuclear compartments (nucleoli, PML bodies, replication foci)

  • Super-resolution microscopy techniques for precise localization within nuclear substructures

  • Live-cell imaging with fluorescently-tagged proteins to track dynamic relocalization during cell cycle or after DNA damage

• Chromatin association analysis:

  • ChIP protocols optimized for replication fork proteins

  • Sequential ChIP (re-ChIP) to identify genomic regions where CTF18 co-localizes with specific partners

  • Chromatin fractionation followed by western blotting to quantify the chromatin-bound fraction

• Cell cycle-specific analysis:

  • Synchronization protocols (double thymidine block, nocodazole arrest) followed by release and time-course sampling

  • Flow cytometric analysis combining CTF18 antibody staining with DNA content measurement

  • Correlation with cell cycle markers (Cyclin A, Cyclin B1, etc.)

These approaches should be adapted based on whether researchers are investigating CTF18's role in normal DNA replication or its checkpoint functions during replication stress.